Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 104,901
  • Shares Outstanding, K 42,470
  • Annual Sales, $ 70 K
  • Annual Income, $ -43,890 K
  • 36-Month Beta 1.74
  • Price/Sales 1,486.48
  • Price/Cash Flow 0.00
  • Price/Book 0.82

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +11.76%
on 05/09/17
2.98 -17.11%
on 05/15/17
+0.10 (+4.22%)
since 04/26/17
3-Month
2.05 +20.49%
on 02/28/17
2.98 -17.11%
on 05/15/17
+0.43 (+21.08%)
since 02/24/17
52-Week
1.98 +24.75%
on 02/08/17
4.15 -40.48%
on 06/08/16
-1.30 (-34.48%)
since 05/26/16

Most Recent Stories

More News
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented...

ECYT : 2.47 (+0.82%)
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

AZN : 33.85 (-1.43%)
LLY : 78.05 (-0.37%)
ECYT : 2.47 (+0.82%)
PFE : 32.14 (-0.06%)
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

GALE : 0.56 (-3.45%)
BTX : 3.25 (-0.91%)
ECYT : 2.47 (+0.82%)
INFI : 1.72 (-1.15%)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss

Endocyte reported a loss per share of 27 cents per share while our consensus called for a loss of 28 cents per share.

ECYT : 2.47 (+0.82%)
Investor Network: Endocyte, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 10, 2017 / Endocyte, Inc. (NASDAQ: ECYT) will be discussing their earnings results in their Q1 Earnings Call to be held May 10, 2017 at 8:30 AM Eastern Time.

ECYT : 2.47 (+0.82%)
Endocyte Announces First Quarter 2017 Earnings Conference Call

Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 10th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational...

ECYT : 2.47 (+0.82%)
What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?

Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.

RARE : 55.91 (-4.46%)
ECYT : 2.47 (+0.82%)
FGEN : 27.25 (+0.37%)
GILD : 64.50 (-0.09%)
Endocyte (ECYT) Up 3.5% Since Earnings Report: Can It Continue?

Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ECYT : 2.47 (+0.82%)
Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment

- Late-breaking poster demonstrates that Endocyte's bi-specific adaptor molecules can mitigate or eliminate cytokine storms -

ECYT : 2.47 (+0.82%)
5 Cheap Breakout Stocks for Superb Returns

The technique identifies those stocks whose prices are fluctuating within a specific band.

ITCI : 10.16 (-3.15%)
ALQA : 0.38 (unch)
ECYT : 2.47 (+0.82%)
RIGL : 2.39 (-1.24%)
NMM : 1.70 (+2.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Support & Resistance

2nd Resistance Point 2.52
1st Resistance Point 2.49
Last Price 2.47
1st Support Level 2.42
2nd Support Level 2.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.